Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.

All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard 2 Boardroom® staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Personalized Medicine for Cancer Treatment

Immuno-oncology represents the new wave of personalized medicine. Scientists at the University of Kansas have developed an innovative approach to activate intracellular signaling pathways that enhance T cell activation, expansion, and differentiation.

Chimeric antigen receptors (CARs) are engineered T cell receptors (TCRs) that are grafted onto T cells obtained from cancer patients. The newly modified T cells are reintroduced into the cancer patient. Because the T cell receptor is engineered to include an antibody that specifically matches the patient's cancer, the newly introduced T cells are able to recognize and kill the cancer cells. There is potential for CAR-T therapy to treat cancer, however, there are significant side effects. In order to improve the safety profile of these therapies, KU researchers incorporated engineered CAR into the endogenous T cell receptor (TCR) complex - resulting in tighter control and regulation.


-Individualized cancer therapy offers the potential for significant improvement in outcomes.

-Precise activation and signaling kinetics; thereby promoting more efficient tumor destruction as compared to other techniques.

-Can be tailored to recognize multiple tumor antigens and immunomodulatory molecules.

-Graft-vs-host disease



-Broadly applicable, highly successful in patients on trial

-Likely to work in combination with a number of current cancer therapies.

-Engineered T cells are constitutively active, resulting in exhaustion and inability to respond to repeated or sustained exposure

-CAR-expressing T cells fail to expand and persist as memory cells

-Cytokine release syndrome that results from rapid and robust activation of CAR-expressing T cells.

Additional Details


University of Kansas

Intellectual Property Protection

Pending Patent

Interested? Request More Information